Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Physiomics Plc LSE:PYC London Ordinary Share GB00BDR6W943 ORD 0.4P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 6.40 3,145,289 10:42:19
Bid Price Offer Price High Price Low Price Open Price
6.30 6.50 6.40 5.95 6.35
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.72 -0.20 -0.14 6
Last Trade Time Trade Type Trade Size Trade Price Currency
16:15:40 O 5,842 6.35 GBX

Physiomics (PYC) Latest News

More Physiomics News
Physiomics Takeover Rumours

Physiomics (PYC) Discussions and Chat

Physiomics Forums and Chat

Date Time Title Posts
14/8/202018:35Physiomics - Cancer Treatment tech firm working with Merck + Oxford Uni7,325
31/7/202007:14PHYSIOMICS plc Virtual Tumor platform4,955
30/9/201908:08PYC - Podcast-
07/8/201915:36Physiomics with Charts & News13,716
01/12/201719:18RGP NEXT MULTI BAGGER TODAY 50p4

Add a New Thread

Physiomics (PYC) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2020-08-14 15:15:416.355,842370.97O
2020-08-14 14:53:226.3776,9234,900.00O
2020-08-14 14:52:376.357,701489.01O
2020-08-14 14:51:236.302,742172.75O
2020-08-14 14:50:146.1580,0004,919.04O
View all Physiomics trades in real-time

Physiomics (PYC) Top Chat Posts

DateSubject
14/8/2020
09:20
Physiomics Daily Update: Physiomics Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker PYC. The last closing price for Physiomics was 6.40p.
Physiomics Plc has a 4 week average price of 5.95p and a 12 week average price of 3.60p.
The 1 year high share price is 17.10p while the 1 year low share price is currently 1.35p.
There are currently 97,334,778 shares in issue and the average daily traded volume is 2,529,629 shares. The market capitalisation of Physiomics Plc is £6,229,425.79.
24/7/2020
20:42
the stigologist: This video has now clocked up 1500 views ! It really is a must watch for any Physiomics shareholders, newbies and prospective shareholders Physiomics has all the elements in place to become a UK Tempus Tempus is a $5bn 'startup' in the USA. Led by a very credible CEO/Founder. It has former FDA Governor Scott Gottlieb on the Board. At some point I suspect Tempus or another huge US healthcare concern will look to partner or buy Physiomics and we will be talking a PYC share price in the multiples of 100p then IMO This. Is. Personalised. Oncology. htTps://twitter.com/Stockonomist/status/1286636723271860225?s=20
22/7/2020
13:49
the stigologist: Check out this video folks...in tweet link below I came across this Company (Tempus) a few weeks back. It's a Personalised Oncology Precision Medicine 'Start-up' set up by ex Groupon founder and valued at $5bn Now it's all very well reading about these peers/comparators of Physiomics but it is another thing to actually see/hear them explain their business model and how they see the market/growth potential And this video does that really effectively. Now I'm not saying Physiomics can go toe to toe with big US VC funded startups like this but this market is going to be HUGE, there is going to be a landgrab phase at some point where all the Unicorn startups face off with Big Tech (Google, Microsoft) etc over who owns people's data and can then mines that data to offer healthcare solutions To my mind UK players have an immense USP in any coming land grab because they will have some priority access to the goldmine that is NHS data but also the links with UK academics/clinicians in these fields On top of those advantages Physiomics has a long history of developing its Virtual Tumour model in association with likes of Merck, Lilly, MSD, ICR, CRUK etc etc which give it a huge body of really specialised proprietary data in this field So now I think its only a matter of time before PYC either go big or get eaten by bigger players They've told us they are already "in discussions with Established Players in the Personalised Medicine field'" to commercialise their Precision Dosing tool and frankly any news on that could blow this share price out of the water (forget just announcing a New Large Pharma (for which there should be a domino effect at some point anyway)) because whilst doing consultancy work for Large Pharma is great and pays the bills and adds proprietary specialist data/algorithms to the core Virtual Tumour model it only justifies a share price in the 25-50p range (on a par with SLP and SDGR). Getting into the Personalised Medicine space brings up potential for 'multiples of 100p' type share price projections htTps://twitter.com/Stockonomist/status/1285634369667858432?s=20
16/7/2020
21:17
the stigologist: PYC Very strong chart with confluence of positive technical indicators - Golden Cross - Bull Flag / Pennant - Volume Fundamentals suggest potential for serious upside e.g. PYC Mkt Cap £7m (at 7p) Comparators RENX Mkt Cap £380m (zero revenue) $SLP Simulations Plus Mkt Cap $1000m $SDGR Schrodinger Mkt Cap $6000m Physiomics brokers Hybridan comment : "...multiple potential catalysts for share price appreciation..." Link to Hybridan write-up hTtps://masterinvestor.co.uk/equities/stocks-in-focus-physiomics/
06/7/2020
13:22
the stigologist: Not sure what the purpose of that trifling and inconsequential RNS was. I know some muppets think those cost money. They don't. I choose to see it as Dr Millen being keen to be totally above board in his personal dealings and eager to insure i's are dotted and t's crossed prior to the upcoming what I expect to be series of newsflow Whilst it will be interesting to see (IF the details are released!) 1) who the Large Pharma is 2) the value of the contract 3) any hints as to potential for repeat business etc i don't think it's the biggest potential news Hybridan the Company brokers told us they see "multiple potential catalysts for share price appreciation" The Placing RNS included 3 of 6 bullet points relating to Personalised Medicine so i think it's missing the bigger picture to fixate on one customer in what is the bread and butter part of the business. There are absolute behemoths (Google Deepmind and Jeff Bezos/Bill Gates funded GRAIL Inc involved in personalised medicine and plenty of UK unicorns like Deepmind/ Benevolent AI). This area is hot and holds such potential Companies are valued in the hundreds of millions on zero revenue. Just look at RENX Renalytix which does AI/ML in kidney diagnostics. A £300m+ valuation on zero revenues! Physiomics have told us they are " discussions with established players in the field". Get the right partner to commercialise our cancer dosing tool and we could see PYC at 100p+ (never mind the 20p+ a Large Pharma deal should see us at) PYC management have told us before they believe Personalised Medicine is 'exciting blue sky' bit of the company. Worth noting the tweet from their partner Merck KGaA this week that PYC re tweeted out. A few companies Merck collaborating with on AI/ML were mentioned. However i didn't see any mention of Palantir (Peter Thiels AI/ML Company valued at c.$40 Billion) which has a Cancer Analytics JV with Merck. That JV was entered into about the same time PYC made public their deal with Merck. Physiomics may not be involved in that Merck venture but demonstrates how leading edge Merck are and the involvement of huge US tech companies in Personalised Medicine.
05/7/2020
11:37
the stigologist: Whilst it will be interesting to see (IF details released!) 1) who the Large Pharma is 2) the value of the contract 3) any hints as to potential for repeat business etc i don't think it's the biggest potential news Hybridan the Company brokers told us they see "multiple potential catalysts for share price appreciation" The Placing RNS included 3 of 6 bullet points relating to Personalised Medicine so i think it's missing the bigger picture to fixate on one customer in what is the bread and butter part of the business. There are absolute behemoths (Google Deepmind and Jeff Bezos/Bill Gates funded GRAIL Inc involved in personalised medicine and plenty of UK unicorns like Deepmind/ Benevolent AI). This area is hot and holds such potential Companies are valued in the hundreds of millions on zero revenue. Just look at RENX Renalytix which does AI/ML in kidney diagnostics. A £300m+ valuation on zero revenues! Physiomics have told us they are " discussions with established players in the field". Get the right partner to commercialise our cancer dosing tool and we could see PYC at 100p+ (never mind the 20p+ a Large Pharma deal should see us at) PYC management have told us before they believe Personalised Medicine is 'exciting blue sky' bit of the company. Worth noting the tweet from their partner Merck KGaA this week that PYC re tweeted out. A few companies Merck collaborating with on AI/ML were mentioned. However i didn't see any mention of Palantir (Peter Thiels AI/ML Company valued at c.$40 Billion) which has a Cancer Analytics JV with Merck. That JV was entered into about the same time PYC made public their deal with Merck. Physiomics may not be involved in that Merck venture but demonstrates how leading edge Merck are and the involvement of huge US tech companies in Personalised Medicine.
19/6/2020
20:22
davevt: Because many of the contracts are done for free, as sweetners, or they consist of next to nothing, just to get an rns to try and peak the share price, also Jim probably realised every rns with a price in it brought the share price down, as they only charge 35k for a project.
12/6/2020
23:13
the stigologist: I have taken the time to annotate Physiomics recent RNS regarding a Fundraise (27th May 2020). My notes are in blue text The fundraise level was at 3.5p but the shares closed this week close to 5p which represents, I believe, evidence of a well executed Fundraise because it seems there was little retail/bucket shop involvement and any Institutions partaking seem to be buying in the secondary market providing a strong underlying bid to the stock. Company : Physiomics Ticker : PYC Share Price : 4.70p Shares o/s : 95.6m Market Cap : £4.5m Cash : £1.2m (comprising £0.4m at y/e 2019 + Placing proceeds of £0.8m) Revenue (CY 2019) : £0.8m Price/Revenue : 5.5x htTps://investegate.co.uk/physiomics-plc--pyc-/rns/fundraise/202005270700070019O/ Physiomics completes £0.83m (gross) fundraise to fund growth opportunities Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models and its Virtual Tumour™ technology to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce that it has completed a placing and subscription, conditional on Admission, to raise approximately £828,750 (gross) from the issue of 23,678,571 new ordinary shares of 0.4p each ("Ordinary Shares") at an issue price of 3.5p per share, through Hybridan LLP (the "Fundraise"). In the last few years, the Company has made significant progress, including: • 70% compounded annual growth in total income FY 2017- 2019, culminating in its highest ever total income in FY 2019 of £783k • >£1m of contracts announced with Merck KGaA since master services agreement announced in November 2017 • Significant new clients CellCentric Ltd (Apr 2018) and Bicycle Therapeutics plc (June 2019) added and repeat contracts signed with both • Completion of a second Innovate UK grant project focused on personalised treatment of advanced prostate cancer (May 2019) and subsequent presentation of results at NIHR event at Royal Marsden Hospital • Award of NIHR i4i grant (March 2020) to undertake an observational trial to generate data in support of personalised dosing tool in advanced prostate cancer • Entering into discussions with companies with an established presence in the field of personalised medicine with a view to exploring how its technology could be commercialised [NOTE : Of the 6 bullet points 3 are related to Personalised Medicine. Physiomics comparitors in its core M&S business are valued at 15-30x Revenue ! BUT Companies in the Personalised Medicine AI/ML space can be valued at HUNDREDS of Millions e.g. Google took over Deepmind for $500m in 2014 ; Benevolent AI is a £1bn+ Unicorn)] On 3 March 2020, the Company announced, as part of its unaudited interim results statement, that it held cash and cash equivalents of £434k as at 31 December 2019 and that it had achieved a small positive cash inflow for the six months ended on the same date. On 19 March 2020, the Company further confirmed that it had a strong pipeline of work and the Directors believe that this has been further strengthened since that announcement. [NOTE : Physiomics already had CASH and was CASHFLOW positive so why raise money ? In my experience when Companies with enough cash raise money it's because a Large Potential Customer is considering a large contract and they want to be sure that the much smaller player will be around to service them in ANY CIRCUMSTANCES so require evidence of a significantly stronger Balance Sheet... and guess what...] In this regard, in the last two working days, the Company has received a strong indication that a significant contract is likely to be signed with a new large pharmaceutical client, with which it has been in discussions since late 2019. While is it still possible that the potential new client could withdraw, it is the Directors' opinion that this is unlikely. Should the contract be signed, the work is expected to take two of our technical staff around five months to complete. [NOTE : Physiomics main employees all have backgrounds with GSK and AZN which could point to the 'Large Pharma' being one of those ? There are c.50 Large Pharmas worldwide and outsourcing of specialist but non-core functions like Modelling & Simulation is a big growth industry so even if it isn't GSK or AZN this time, I would expect them to get involved later. One of the major advantages of PYC tech is ability to model combination treatments. Interesting in this regard that PYC's existing Big Pharma customer Merck has major collaborations with Big Pharma like GSK and Pfizer combining treatments in the exact Immuno-oncology space Physiomics software plays into] In order to further develop its business, the Company is raising funds through the Fundraise to enable it to carry out activities including increasing its sales & marketing spend, recruiting a further member of its technical team and further investing in its personalised medicine technology as well as for general working capital purposes. Director Participation in the Fundraise Dr Jim Millen (CEO), Dr Paul Harper (Chairman) and Dr Christophe Chassagnole (COO) have participated in the Fundraise in the amounts of £3,000, £5,000 and £3,000 respectively (the "Directors' Participation") and will be issued 85,715 Ordinary Shares, 142,857 Ordinary Shares and 85,715 Ordinary Shares respectively. On Admission, Dr Millen, Dr Harper and Dr Chassagnole will be interested in, in aggregate, 530,356, 668,564 and 602,723 Ordinary Shares respectively, representing 0.55%, 0.70% and 0.63%, of the Company's then enlarged issued share capital. [NOTE : This is the first time I can recall that ALL Physiomics Directors participated with their own money in a Placing. Some have made derogatory comments about the 'size' of the involvement. Fact of the matter is many People do not have a lot of spare cash to throw at Investments, one would imagine Directors already have exposure to PYC they should if anything diversify not concentrate exposure, however Management collectively own Shares and Options exceeding 6% of the Company so they are well incentivised and aligned with shareholders] Dr Jim Millen, CEO said: "We are delighted by the response to this over-subscribed fundraise. We thank our current shareholders for their continued support and have achieved another milestone by welcoming our first small-cap institutional fund onto the register. We believe this is reflective of our strong commercial traction over the last four years. Our team is committed to continuing to support global pharma and biotech companies in their drug discovery and development endeavours, and these funds will be mainly focused on growing our already strong pipeline of new business opportunities. I look forward to continuing to update shareholders on our progress."
17/5/2020
11:05
the stigologist: One of the problems PYC Physiomics has had getting the respect/valuation it deserves has been the lack of a decent UK quoted comparitor to help analysts and investors gain a better understanding of the market it operates in, the industry dynamics and the appropriate valuation benchmark Although there still remains no viable UK comparitor in recent months an interesting US comparitor has emerged which may help Investors understanding and appreciation of PYC What is interesting is that this is no ordinary comparitor. This Company has been described by Citron Research as a 'Tesla type' industry disruptor, the most important IPO in the last 5 years and has Bill Gates and D.E.Shaw as major cornerstone investors (together owning c.50%). Citron Research are mainly known as a specialist 'Bear' research house often debunking 'hot' stocks so it's interesting that they are so positive on this particular concept stock. The stock in question is SDGR Schrodinger a Company founded in 1990, the current CEO joined in c.2002. It has taken them up now to IPO (February 2020) since when the stock has tripled ! ($17 to $55) and the Company is currently valued at over 30x (yes THIRTY times!) Revenue (2019 revenue $86m ; Mkt Cap $2.7bn) The underlying story of Schrodinger is that of applying computer modelling techniques to drug discovery. Global Pharma/Biotech spends c.$180bn a year on R&D. So SDGR has a potentially huge market still left to penetrate. Faced with a US tech comparitor the usual response from UK cuck analysts/Fund Managers is 'well US equity investors apply higher ratings to US stocks that's just the way it is' However there is very good reason to make the case that Physiomics should not only be valued at 30x revenue but could deserve a premium! SDGR is valued at 30x Revenue because US investors believe it has a wide open growth opportunity to eat into the $180bn Global Pharma R&D market opportunity If US investors are prepared to pay so much for future growth how much would PYC be worth as a 'growth option' acquisition for either SDGR or a peer such as Private Equity roll-up Certara ? - PYC would give SDGR access to computer based modelling and simulation expertise in the Drug Development part of the R&D cycle rather then just Drug Discovery - PYC would give SDGR access to European geography - PYC would give SDGR access to customers SDGR might not otherwise have access to (Merck, Bicycle Therapeutics) Applying a 30x valuation to PYC's trailing 12 month revenues would imply a valuation of £23m (compared to the current £2.9m) a share price of 32.5p versus current 4p NB : That valuation applied to Physiomics 'bread and butter' modelling and simulation business which is analagous to Schrodinger. Physiomics also have a 'blue sky' story in utilising their Virtual Tumour cancer modelling expertise to offer a 'Business to Consumer' Universal Cancer Decision Support System through NHS/Clinicians which could be worth... well name your price. UK unicorns in AI/ML pharma/bio space are valued at Billions on zero revenue.
27/12/2017
11:08
margic: It's a good thing for the PYC share price that eyes have just come off this. As buyers start to return this can move very very quick before the herd arrive and when the herd arrive we spike. Signal to take profit and re-load as the herd exit with their losses and smaller profits. Hope to see this 10p+ before volumes really pick up. Keep watch as PYC can flash bang wallop!
18/12/2017
09:06
the stigologist: Todays VAL Valirx news on VAL201 is also great news for PYC. Expect PYC share price to follow VAL up
Physiomics share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
PYC
Physiomics
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200814 23:25:01